Good MorningEquity markets pulled back from the recent high following the FOMC minutes. The minutes showed that the Fed was worried about the lack of progress on inflation and was ready to hike rates again if necessary. The tone contradicts what the market expected, reducing the odds of a rate cut this year. Without an appreciable improvement in the pace of inflation, the FOMC may have no choice but to keep policy tight if it does not raise rates again.
The market's reaction to the news was light, considering the impact on the economic outlook. The S&P 500's move lower shed less than 1% at the session's low and showed some support at the short-term moving average. Support is due to hopes for earnings growth centered on NVIDIA. NVIDIA is expected to post another blowout quarter driven by AI demand and send its and other AI-centric tech stocks to new highs. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Discretionary | |
Global-e Online (NASDAQ: GLBE) is succeeding because it offers three things merchants need in one place: eCommerce, direct-to-consumer access, and international expansion. eCommerce is entrenched in our lives and a requirement for any business today. International expansion, specifically cross-bor... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Technology | |
NVIDIA (NASDAQ: NVDA) produced another beat-and-raise quarter that says one thing: as much hype as there is about the AI industry, the market grossly underestimated the impact and importance of NVIDIA semiconductors. The company’s results are so above the consensus estimate they are mind-bog... Read the Full Story |
|
Consumer Discretionary | |
Every once in a while, the market's volatility index (the VIX) goes to an extreme. Whether to the upside or downside, these significant swings bring about massive opportunities for investors who know how to ride the market's volatility cycle. Today, the VIX sits between 11.5% and 13.0%, levels not... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
Analog Devices (NASDAQ: ADI) share prices are surging because a trough is in place, and the outlook is robust. The FQ2 results and guidance for FQ3 aren't robust but show markets stronger than expected, and AI supports the pivot back to growth. End-market inventory normalization is expected for se... Read the Full Story |
|
Consumer Discretionary | |
TJX Companies (NYSE: TJX) industry-leading position in off-price retail and quality operations will soon lead its stock price to new heights. Like Walmart (NYSE: WMT), TJX Companies benefits from the high inflation and interest rate environment because shoppers are still flush but turning more to ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
“Be fearful when others are greedy, and greedy when others are fearful.”
Warren Buffett said it best: Great investing often involves seeking out unloved names that the market has overlooked or undervalued.
While it's tempting to buy popular stocks like NVIDIA (NASDAQ: NVDA) and Tesla... Read the Full Story |
|
Technology | |
After reporting its first quarter 2024 earnings report, shares of Zoom Video Communications Inc. (NASDAQ: ZM) shook markets by initially plummeting as much as 4.6% from their closing price and swiftly rising back to show a 2.5% premium to the day’s end. To put this price action simply, a sig... Read the Full Story |
|
Finance | |
A 5% dip during Tuesday’s session was the latest in a run of red days for Wayfair Inc (NYSE: W) stock. It came as it did in the days after the benchmark S&P 500 index set a fresh all-time high, which will have made it worse for investors.
They’d have been forgiven for thinking at... Read the Full Story |
|
|
Consumer Discretionary | |
Investors looking for worthwhile companies to add to their portfolios should consider a few factors that make up a ‘high-quality’ stock. The company’s product or service and the relative moat around them are among these factors. Moat is a word today’s newer retail investors... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida. | | View Today's Stock Pick |
|
Many new investors are surprised...